Federico Nichetti
@fedenichetti.bsky.social
Medical Oncologist @iov_irccs | Research fellow in Computational Oncology @DKFZ - @NCT_HD | Proud #cysticfibrosis patient
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma - @myesmo.bsky.social www.esmoopen.com/article/S205...
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma
Ampullary carcinoma (AC) is a rare disease with an abysmal prognosis and few treatment
options. The molecular landscape and its therapeutic implications remain inadequately
understood. This study aims...
www.esmoopen.com
July 12, 2025 at 9:58 AM
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma - @myesmo.bsky.social www.esmoopen.com/article/S205...
www.cell.com/one-earth/fu... As much as I don’t like doctors say “MY patient” rather than “I patient I treat”, I don’t like researchers say “MY study, MY project”. Science is sharing.
Systemic territoriality in academia: The Gollum effect’s impact on scientific research and careers
Scientific progress depends on open collaboration and thus resource sharing, but possessive
and territorial behaviors, which we call the Gollum Effect, threaten this ideal. This
study reveals widespre...
www.cell.com
May 21, 2025 at 6:57 PM
www.cell.com/one-earth/fu... As much as I don’t like doctors say “MY patient” rather than “I patient I treat”, I don’t like researchers say “MY study, MY project”. Science is sharing.
Reposted by Federico Nichetti
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
jamanetwork.com
December 26, 2024 at 8:55 PM
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Reposted by Federico Nichetti
New online! PDAC: advances in tumour microenvironment, microbiome and AI
PDAC: advances in tumour microenvironment, microbiome and AI
Nature Reviews Gastroenterology & Hepatology, Published online: 20 December 2024; doi:10.1038/s41575-024-01030-yPancreatic cancer remains one of the most challenging malignancies, with a very poor prognosis. Current research is focused on elucidating the…
go.nature.com
December 20, 2024 at 6:36 PM
New online! PDAC: advances in tumour microenvironment, microbiome and AI
ascopubs.org/doi/10.1200/... Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
PURPOSEThe ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine
(GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently,
the PRODIGE24-CC...
ascopubs.org
December 7, 2024 at 8:27 AM
ascopubs.org/doi/10.1200/... Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Reposted by Federico Nichetti
Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 30, 2024 at 12:54 PM
Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Novel Therapies for Pancreatic Cancer ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
November 27, 2024 at 7:02 AM
Novel Therapies for Pancreatic Cancer ascopubs.org/doi/10.1200/...
“Recognizing that oncology practice remains, to some extent,
an art, it is dif cult to measure what makes any of us
competent, compassionate, and effective oncologists” ascopubs.org/doi/10.1200/...
an art, it is dif cult to measure what makes any of us
competent, compassionate, and effective oncologists” ascopubs.org/doi/10.1200/...
Did I Mess Up Today? | JCO Oncology Practice
ascopubs.org
November 20, 2024 at 5:58 PM
“Recognizing that oncology practice remains, to some extent,
an art, it is dif cult to measure what makes any of us
competent, compassionate, and effective oncologists” ascopubs.org/doi/10.1200/...
an art, it is dif cult to measure what makes any of us
competent, compassionate, and effective oncologists” ascopubs.org/doi/10.1200/...